GA-FARM-TO-PLATE
28.2.2023 21:34:42 CET | Business Wire | Press release
Today, Farm to Plate announced the immediate availability of Farm To Plate (F2P), a pioneering blockchain-based provenance and tracking product for the Food supply chain that will expand the scope of data transparency to the grassroots of the food industry – end-to-end, from the producers to the consumers. The Farm to Plate platform addresses increased regulatory demands for digitization and transparency through GS1 and FDA FSMA Rule #204 compliance and heightens brand trust, financial stability, and reputation by enabling a focus on sustainability, responsible farming, consumer transparency, and significantly reduced recall risk and size. See how it works.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006317/en/
Key Features and Benefits of Farm to Plate
- Microtipping: Enables direct tips to producers from end consumers that are securely, instantaneously transmitted over the blockchain, eliminating middlemen and chances of fraud while giving producers a great boost to their meager revenues.
- Immutable, end-to-end tracking and trace: Immutable, decentralized information ensures no single stakeholder has disproportionate information ownership, eliminating the risk of data fudging.
- Secure access control for information on the blockchain: Strong access controls enable granular control over who has access to what data, ensuring only relevant, required information is accessible to different parties.
- Built on GS1 standards and compliant with FDA FSMA Rule #204.
Fulfilling Consumers’ Need for End-to-end Transparency
In a globalized food supply chain where food is sourced and transported across continents, the level of transparency, from sourcing, transportation, to storage and other details, that consumers are now demanding is unprecedented. Research also proves that 73% of consumers prefer brands that are sustainable, honest, and transparent about how and where products were raised or grown. Sustainable production is also high on their wishlist, with them being willing to pay a huge premium - anywhere from 30% to 40% on average – for sustainably produced goods. “Farm to Plate will be revolutionary for food brands looking to develop a strong identity with the sustainability-focused modern consumer. By enabling transparency and the ability to directly connect to their suppliers, brands can project a strong image as a modern, conscious corporation to their customers. This is the beginning of a long journey of trust between consumers and food brands.”- Mika Liss, Strategic Advisor, Farm To Plate.
Farm to Plate Fills the Missing Links in the Supply Chain
Food brands are struggling with the weight of regulatory requirements and the consumers’ transparency demands. Providing such in-depth and reliable information in a complex global supply chain poses challenges. There is heavy dependency on manual processes making data vulnerable to fraud and preventing timely information from passing to all stakeholders. Farm to Plate uses permissioned blockchain, AI-driven tools, and automation through IoT devices to provide access-controlled, immutable, real-time data to the right stakeholders. “We’ve built F2P with open, industry-standard technology that integrates seamlessly with your existing systems. And the best part about it is, it’s modular, allowing us to extend its capabilities almost infinitely as we build out features in future releases.”- Saptarshi Choudhury, VP of Product at Farm To Plate.
Connecting Consumers and Farmers for Sustainable Ecosystems
Through innovative use of popular messaging platforms such as WhatsApp, voice transcription, vernacular language translations and offline functionality, Farm To Plate is the first track and trace solution truly accessible to the fisherman and farmer. Through microtipping, Farm to Plate will leverage the consumer-farmer connection to bring financial stability to the producer community and reduce the risk of overfarming.
“Farm To Plate is the first food supply chain solution that will connect every stakeholder to the other, and make them part of the system. Uniquely, we connect consumers and farmers directly - enabling consumer food trust through transparency and financial sustainability for producers through a single QR code. Our value proposition is enshrined in the 5 Ts: Trace, Track, Trade, Tip, Trust – and Tip is our favorite because it acknowledges the farmer.”- Pramod Sajja, President and CEO, Farm to Plate LLC. & Paramount Software Solutions Inc.
About Farm to Plate
The vision of the Blockchain team of Farm to Plate was to develop a product to transform the way the food and beverage industry operates. The success stories of Hyperledger Fabric resulted in its adoption to enable bringing the open-source ecosystem to the forefront of this technology. Farm to Plate wanted to build something that made a difference, and yet simple to adapt to fill the gaps in the existing food supply chain systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
